# EDGAR Filing Document

**Accession Number:** 0001827506
**File Stem:** 0001827506-25-000072
**Filing Date:** 2025-6
**Character Count:** 7354
**Document Hash:** 343a1ceba169036b8a6856faef75be8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001827506-25-000072.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001827506-25-000072

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250604

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tourmaline Bio, Inc.
- **CENTRAL INDEX KEY:** 0001827506
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40384
- **FILM NUMBER:** 251030632

**BUSINESS ADDRESS:**
- **STREET 1:** 27 WEST 24TH STREET
- **STREET 2:** SUITE 702
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 646-481-9832

**MAIL ADDRESS:**
- **STREET 1:** 27 WEST 24TH STREET
- **STREET 2:** SUITE 702
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Talaris Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201007

?xml version='1.0' encoding='ASCII'? trml-20250604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): June 4, 2025**

**___________________________________**

**TOURMALINE BIO, INC.**

**(Exact name of registrant as specified in its charter)**

**___________________________________**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware**<br>**(State or other jurisdiction of** <br>**incorporation or organization)** | **001-40384**<br>**(Commission** <br>**File Number)** | **001-40384**<br>**(Commission** <br>**File Number)** | **83-2377352**<br>**(I.R.S. Employer** <br>**Identification No.)** |
| **27 West 24th Street, Suite 702**<br>**New York, NY**<br>**(Address of principal executive offices)** | **27 West 24th Street, Suite 702**<br>**New York, NY**<br>**(Address of principal executive offices)** | **10010**<br>**(Zip Code)** | **10010**<br>**(Zip Code)** |
| **Registrant's telephone number, including area code: (646) 481-9832** | **Registrant's telephone number, including area code: (646) 481-9832** | **Registrant's telephone number, including area code: (646) 481-9832** | **Registrant's telephone number, including area code: (646) 481-9832** |
| **Not Applicable**<br>**(Former Name or Former Address, if Changed Since Last Report)** | **Not Applicable**<br>**(Former Name or Former Address, if Changed Since Last Report)** | **Not Applicable**<br>**(Former Name or Former Address, if Changed Since Last Report)** | **Not Applicable**<br>**(Former Name or Former Address, if Changed Since Last Report)** |

---

**___________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading** <br>**Symbol** | **Name of each exchange** <br>**on which registered** |
| Common Stock, par value $0.0001 per share | TRML | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 4, 2025, Tourmaline Bio, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). A total of 25,684,479 shares of common stock were entitled to vote as of April 15, 2025, the record date for the Annual Meeting. There were 20,804,265 shares of common stock present virtually or represented by proxy at the Annual Meeting, constituting a quorum to conduct business.

The following proposals were voted upon at the Annual Meeting:

---

| | |
|:---|:---|
| Proposal No. 1 | Election of Dr. Caley Castelein and Aaron Kantoff as Class I directors to the Company's board of directors, each to serve until the 2028 annual meeting of stockholders; and |
| Proposal No. 2 | Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. |

---

On June 4, 2025, Mediant Communications, Inc., the independent inspector of election for the Annual Meeting, delivered its final report as to the voting results for each of these proposals. The following are the final voting results for each of the items voted on at the Annual Meeting:

**Proposal 1. Election of Class I Directors.**

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Dr. Caley Castelein | 14,926,508 | 2,653,512 | 3,224,245 |
| Aaron Kantoff | 16,496,989 | 1,083,031 | 3,224,245 |

---

Based on the votes set forth above, the stockholders of the Company elected Dr. Caley Castelein and Aaron Kantoff as Class I directors to the Company's board of directors, each to serve until the 2028 annual meeting of stockholders.

**Proposal No. 2. Ratification of Selection of Deloitte & Touche LLP.**

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 20,799,312 | 3,257 | 1,696 |

---

Based on the votes set forth above, the stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm to serve for the year ending December 31, 2025.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **TOURMALINE BIO, INC.** | **TOURMALINE BIO, INC.** |
| Date: June 6, 2025 | By: | /s/ Brad Middlekauff |
|  | Name: | Brad Middlekauff |
|  | Title: | Corporate Secretary |

---